Monica R Gadelha
Overview
Explore the profile of Monica R Gadelha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
2465
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loughrey P, Mothojakan N, Iacovazzo D, Arni A, Aflorei E, Arnaldi G, et al.
Eur J Endocrinol
. 2025 Mar;
PMID: 40070360
Objective: Heterozygous germline loss-of-function variants in AIP are associated with young-onset growth hormone and/or prolactin-secreting pituitary tumours. However, the pathogenic role of the c.911G>A; p.(Arg304Gln) (R304Q) AIP variant has been...
2.
Isand K, Arima H, Bertherat J, Dekkers O, Feelders R, Fleseriu M, et al.
Eur J Endocrinol
. 2025 Feb;
192(3):R17-R27.
PMID: 39973025
The objective of this study was to establish recommendations for thromboprophylaxis in patients with endogenous Cushing's syndrome (CS), addressing the elevated risk of venous thromboembolism (VTE) associated with hypercortisolism. A...
3.
Scaf C, Altoe A, Ventura N, Vincent M, Kasuki L, Gadelha M
Pituitary
. 2025 Feb;
28(2):31.
PMID: 39924607
Introduction: Headache is common among patients diagnosed with pituitary adenoma (PA). There are still controversies regarding the headache presentation, pathophysiology and outcome after treatment in these patients. Objectives: To determine...
4.
Fleseriu M, Pivonello R, Newell-Price J, Gadelha M, Biller B, Auchus R, et al.
Pituitary
. 2025 Jan;
28(1):22.
PMID: 39863744
Purpose: To evaluate the effect of osilodrostat and hypercortisolism control on blood pressure (BP) and glycemic control in patients with Cushing's disease. Methods: Pooled analysis of two Phase III osilodrostat...
5.
Newell-Price J, Fleseriu M, Pivonello R, Feelders R, Gadelha M, Lacroix A, et al.
J Endocr Soc
. 2024 Nov;
9(1):bvae201.
PMID: 39610378
Purpose: To assess whether simultaneous normalization of late-night salivary cortisol (LNSC) and mean urinary free cortisol (mUFC) in patients with Cushing disease treated with osilodrostat is associated with better clinical...
6.
Giardini E, Barbosa M, Ventura N, da Mata Pereira P, Guasti A, Niemeyer P, et al.
J Endocrinol Invest
. 2024 Nov;
48(3):701-709.
PMID: 39499435
Purpose: Nonfunctioning pituitary adenomas (NFPAs) are benign tumors growing in the sellar region. Total surgical excision of the lesion is recommended as the preferred treatment choice with preservation of adjacent...
7.
Botelho L, Dezonne R, Wildemberg L, Lyra Miranda R, Gadelha M, Andreiuolo F
Brain Pathol
. 2024 Oct;
35(1):e13313.
PMID: 39473262
There are five subtypes of somatostatin receptors (SST1-5), which are expressed in several types of solid neoplasms, neuroendocrine tumors, and pituitary adenomas. Most commonly, SST2 and SST5, are of interest...
8.
Karavitaki N, Bettinger J, Biermasz N, Christ-Crain M, Gadelha M, Inder W, et al.
Endocr Rev
. 2024 Oct;
45(6):773-794.
PMID: 39441725
The use and misuse of opioids are a growing global problem. Although the effects of these drugs on the human endocrine system have been studied for decades, attention on their...
9.
Lamback E, Lyra Miranda R, Chimelli L, Andreiuolo F, Kasuki L, Wildemberg L, et al.
Endocr Oncol
. 2024 Oct;
4(1):e240003.
PMID: 39391823
Pituitary gigantism is a rare pediatric disorder caused by excess growth hormone (GH) secretion. In almost 50% of cases, a genetic cause can be identified, with pathogenic variants in the...
10.
Lyra Miranda R, Guterres A, de Azeredo Lima C, Lamback E, Gadelha M
Endocr Pathol
. 2024 Sep;
35(3):269-271.
PMID: 39230646
No abstract available.